Newswise — BALTIMORE, AUGUST 27, 2021 – Rural regions in the U.S. have been disproportionately affected by the opioid epidemic, while also having the fewest number of programs to treat opioid use disorder. In an effort to remedy this dire health issue, University of Maryland School of Medicine (UMSOM) researchers reconfigured a recreational vehicle (RV) as a telemedicine mobile treatment unit to determine whether it could provide effective screening and treatment to individuals with opioid use disorder in rural areas. Their research, published today in the Journal of the American Medical Association (JAMA) Network Open, found that the innovative approach to be as successful as traditional brick-and-mortar treatment clinics. The study also found a significant reduction in illicit opioid use among the majority of patients treated on the mobile unit, as well as sustained success in these patients continuing therapy to avoid relapse.
“We are very encouraged by our findings and hope that our model can be replicated throughout the country in places where patients have limited access to health care providers who can treat opioid use disorder,” said study lead author Eric Weintraub, MD, Professor of Psychiatry and Division Head of Addiction Research and Treatment at UMSOM.
Last year, more than 92,000 Americans died from drug overdoses, a nearly 30 percent increase from 2019, according to a recent report from the Centers for Disease Control and Prevention. Most of these deaths were caused by illicit opioid drugs like fentanyl and heroin. While effective medication-based treatments are available, only 1 in 4 people with opioid use disorder receive such treatments. FDA-approved medications including buprenorphine and methadone are able to prevent withdrawal symptoms and reduce cravings in those who stop using illicit drugs and are reported to significantly decrease overdose deaths. Treatment also can include counseling techniques to encourage motivation to change and prevent relapse.
In the new study, the UMSOM researchers used the mobile health unit to evaluate and treat 94 patients with opioid use disorder, all of whom lived in rural areas along the Eastern Shore region of Maryland. These patients accessed the unit for treatment within 10 miles of their respective homes from June to October 2020 – during the height of the COVID-19 pandemic. The mobile unit was staffed with a nurse, a substance use counselor, and a peer recovery specialist. Patients were provided with in-person screening and counseling as well as access to a physician via a secure videoconferencing link. Buprenorphine or naloxone were electronically prescribed and sent to a patient’s local pharmacy.
The researchers wanted to measure how effective the mobile unit was at maintaining patients in buprenorphine therapy and decreasing their use of illicit opioids. They found nearly 64 percent of patients remained in treatment after two months and 58 percent after three months, rates that are similar to those seen in traditional in-person substance use treatment programs. Opioid use was reduced, on average, by about one-third, which was also similar to what researchers have seen in traditional clinical settings.
“To our knowledge, this is the first of its kind mobile telemedicine unit to treat opioid use disorders in rural communities,” said Annabelle (Mimi) Belcher, PhD, Assistant Professor of Psychiatry at UMSOM. “We have demonstrated that the model works as well as traditional clinics situated in more populated areas, which is an exciting finding.”
UMSOM faculty Chamindi Seneviratne, MD; Jessica Anane, MPH; Kelly Coble, LCSW-C;
Sarah Kattakuzhy, MD; Aaron Greenblatt, MD; Christopher Welsh, MD; and Alexander Pappas, MD were co-authors on this study. The research was funded by a federal grant from the Health Resources and Services Administration. The telemedicine mobile treatment unit was funded by the Maryland Department of Health’s Behavioral Health Administration.
“Providing patients with access to healthcare via telemedicine and mobile health units has become increasingly important during the COVID-19 pandemic, and our UMSOM faculty continue to innovate in this area,” said E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, the John Z. and Akiko K. Bowers Distinguished Professor, and Dean, University of Maryland School of Medicine. "This new study provides evidence that telemedicine and mobile health units really work to provide patients with access to the lifesaving services they need. We will continue to explore other ways to provide mobile healthcare to patients in underserved communities.”
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 student trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu
MEDIA CONTACTRegister for reporter access to contact details
Journal of the American Medical Association (JAMA) Network Open